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Abstract
The “epithelial barrier hypothesis” proposes that the exposure to various epithelial
barrier–damaging agents linked to industrialization and urbanization underlies the
increase in allergic diseases. The epithelial barrier constitutes the first line of physical,
chemical, and immunological defense against environmental factors. Recent reports
have shown that industrial products disrupt the epithelial barriers. Innate and adap-
tive immune responses play an important role in epithelial barrier damage. In addition,
recent studies suggest that epithelial barrier dysfunction plays an essential role in the
pathogenesis of the atopic march by allergen sensitization through the transcutane-
ous route. It is evident that external factors interact with the immune system, trigger-
ing a cascade of complex reactions that damage the epithelial barrier. Epigenetic and
microbiome changes modulate the integrity of the epithelial barrier. Robust and sim-
ple measurements of the skin barrier dysfunction at the point-of-care are of signifi-
cant value as a biomarker, as recently reported using electrical impedance
spectroscopy to directly measure barrier defects. Understanding epithelial barrier
dysfunction and its mechanism is key to developing novel strategies for the
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prevention and treatment of allergic diseases. The aim of this review is to summarize
recent studies on the pathophysiological mechanisms triggered by environmental fac-
tors that contribute to the dysregulation of epithelial barrier function.
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1 | INTRODUCTION
Since the introduction of the “epithelial barrier hypothesis,” factors
that damage the skin and mucosal barriers have become a major
area of interest.1 Epithelial barrier leakiness has been demonstrated
in asthma, atopic dermatitis (AD), allergic rhinitis (AR), chronic
rhinosinusitis (CRS), eosinophilic esophagitis, celiac disease, and inflam-
matory bowel disease.2-9 Leakiness of the gut epithelium is also impli-
cated in systemic autoimmune and metabolic conditions such as
obesity, diabetes, rheumatoid arthritis, multiple sclerosis, systemic lupus
erythematosus, fatty liver, autoimmune hepatitis, and ankylosing spon-
dylitis. Although further studies are needed, microbial dysbiosis and an
impaired gut barrier are suspected in Alzheimer's disease, Parkinson's
disease, chronic depression, and autism spectrum disorders.1 The epi-
thelium is a pivotal structure in host defense because it not only pro-
vides a physical barrier between the environment and the subepithelial
region, but also contributes to the induction of an appropriate immune
response against allergens, pathogens, and noxious stimuli that attenu-
ate the epithelial barrier. Recent studies have shown that a defective
epithelial barrier, with compromised tight junctions (TJs) and adherence
junctions (AJs), is part of the underlying pathology in diseases such as
AD, bronchial asthma, eosinophilic esophagitis, food allergy, CRS, and
AR, which are discussed in this review.3,7,9,10 The sequential develop-
ment of these diseases starting from AD in infancy followed by food
allergy, asthma and rhinitis, commonly known as the atopic march, has
sharply increased.11-13 The inner molecular mechanisms underlying the
epithelial barrier dysfunction involve a type 2 immune response
through type 2 cytokines produced by Th2 cells and type 2 innate
lymphoid cells (ILC2s).14,15 It is well-known that lifestyle changes due
to industrialization cause epithelial barrier dysfunction.16,17 Factors that
have been recognized to damage the epithelial barrier include allergens,
pathogens, commercial detergents, surfactants, emulsifiers in processed
food, cigarette smoke, particulate matter, diesel exhaust, ozone,
nanoparticles, and microplastics.1,18-27 These changes also compromise
epithelial barrier function across multiple organ systems.21,23,25,28-31
Quantitative skin barrier assessment in vivo can be beneficial for many
clinical applications, including diagnosis, follow-up, prevention, and
monitoring the therapy of AD.
Supporting our “epithelial barrier hypothesis,” we discuss recent
advances in our understanding of the mechanisms underlying epithe-
lial barrier dysfunction triggered by environmental and other culprit
factors. The latest technological developments to measure skin barrier
dysfunction are reviewed.
1.1 | Structure of the epithelial barrier
The epithelial barrier consists of a stratified epithelial cellular sheet that
forms a physical barrier on the body surface. Four main components can
be identified: (a) epithelial cells; (b) structural proteins, such as filaggrin,
loricrin, involucrin, and proteins involved in the formation of TJs and AJs;
(c) secreted epithelial products, such as mucus, antimicrobial peptides,
and a lipid-rich matrix composed of ceramides, cholesterol, and free fatty
acids (FFAs); and (d) epithelial microbiota (Figure 1).3,32
The epidermis has its original structure and is composed of four
main layers: the stratum corneum, stratum granulosum, stratum spi-
nosum, and the stratum basale.3 The stratum corneum is the outer-
most layer, consisting of enucleated keratinocytes referred to as
corneocytes. It is maintained by the complex interaction of the corni-
fied envelope, intracytoplasmic moisturizing factors, and a complex
lipid mixture in the extracellular space. Filaggrin is a structural protein
important for the alignment of keratin filaments and the formation of
the cornified envelope and natural moisturizing factor.33-35
TJs are composed of transmembrane proteins, such as claudins,
occludin, zonula occludens (ZOs), and junctional adhesion molecules, which
regulate the paracellular permeability and are located in the stratum
granulosum of the epidermis and mucosal epithelium. Allergens gain rapid
entry across disrupted TJs, engage dendritic/Langerhans cells, and prime
the systemic inflammatory response.3,32 In intact skin, Langerhans cells have
been found essential for immune tolerance in a murine ovalbumin (OVA)-
induced model.36 Epicutaneous sensitization with allergen promotes a local
and systemic type 2–predominant response, characterized by increased
interleukin (IL)-4, IL-5, IL-13, and immunoglobulin E (IgE) (Figure 2).37,38
Many microorganisms colonize the area above and within the
stratum corneum, and mucosa, thereby maintaining immune homeo-
stasis. The epithelial microbial dysbiosis contributes to the develop-
ment and course of allergic disorders such as AD and asthma.39,40 The
mechanism of epithelial barrier dysfunction is not fully understood
and further research is warranted.
1.2 | Culprit factors for epithelial barrier
dysfunction
1.2.1 | Environmental factors
Environmental factors and lifestyle changes may be responsible for
the increasing prevalence of allergic diseases.16,17 The sum of external
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factors that an individual is exposed to throughout life is referred to
as the exposome.41,42 The combination of multiple factors, such as
cigarette smoke, air pollutants, chemicals, aeroallergens, and diet, con-
tributes to the development and exacerbation of asthma and other
allergic diseases.1,43-47
Oxidative stress and air pollution
Cigarette smoke and its reactive oxygen species (ROS) products
impair the epithelial barrier function and increase epithelial permeabil-
ity by triggering the RhoA/Rho-associated protein kinase (ROCK) sig-
naling pathway in which ROCK is activated after hyaluronan
F IGURE 1 Skin and mucosal
barrier structure. The epithelial
barrier of the skin and airways
consists of four main components.
(a): The epithelial layers—the
epidermis consists of four sub-
layers and the airway epithelial
barrier is made of a pseudostratified
epithelium. (b): Structural proteins,
such as filaggrin, natural
moisturizing factor (NMF),
ceramide, tight junctions (TJs), and
adherence junctions (AJs). (c):
Secreted molecules, such as mucin,
anti-microbial peptides, and fatty
acids. (d) Microbiota on the surface
of the epithelial barrier
F IGURE 2 Endogenous and exogenous factors affecting epithelial barrier function. Allergens (eg, house dust mite) and noxious stimuli
(eg, air pollution) attenuate the epithelial barrier function. An impaired skin barrier facilitates the entry of allergens and activation of the innate
immune response. Damaged epithelial cells produce IL-25, IL-33, and TSLP, followed by activation of ILC2 and dendritic cells. Activated dendritic
cells induce type 2 skewing and IgE production by B cells. Type 2 cytokines and degranulation of mast cells exacerbate the inflammation and
further attenuates barrier function. Microbe-associated molecular patterns (eg, CpG DNA) restore epithelial barrier integrity and maintain
epithelial barrier function. DC: dendritic cell, ILC: innate lymphoid cell, EOS; eosinophil, MC: mast cell, TSLP: thymic stromal lymphopoietin,
MAMP: microbe-associated molecular pattern
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fragmentation via ROS, which leads to disruption of AJs through a
decrease in E-cadherin gene and protein expression in human bron-
chial epithelial cells (HBECs).43 Exposure to microplastics and air pol-
lutants, such as diesel exhaust particles (DEPs), ozone, and nitrogen
dioxide, induces the production of ROS.21,44,48-50 Particulate matter
2.5 (PM2.5), the main component of DEP, exacerbated AR through TJ
disruption in a mouse model of allergic rhinitis.51,52 A population-
based prospective study has shown that a 2.3 parts per billion
increase in nitrogen dioxide (NO2) is associated with an increased risk
of prevalent and atopic eczema in male adults.47 Exposure to traffic-
related air pollutants, PM2.5, PM10, and oxides of nitrogen, is associ-
ated with increased odds of incident eczema, particularly PM2.5, and is
more pronounced with nonatopic eczema in elderly women.53 More-
over, DEP exposure induces IL-25, IL-33, and thymic stromal
lymphopoietin (TSLP) expression in the lungs, leading to severe
asthma by activation of the aryl hydrocarbon receptor.28,54
Volatile organic compounds and ozone
Volatile organic compounds (VOCs) are composed of carbon-based
molecules such as formaldehyde, benzene, and toluene that affect the
urban air quality and human health. VOCs are commonly found in
cleaning products, wallpaper, furniture, and plastics, and are main con-
tributors to indoor air pollution.55,56 VOC exposure leads to
proteasome inactivation and protein oxidation, DNA damage, and
apoptosis in keratinocytes and human skin explants.57 Exposure to
formaldehyde for 1 hour increases transepidermal water loss (TEWL)
in both healthy and AD children, supporting the role of short-term
exposure to airborne formaldehyde in impairment of the skin bar-
rier.58 VOCs can react with NO2 in the presence of sunlight to form
ozone,44 which causes airway hyperreactivity, airway inflammation,
and bronchial epithelial barrier disruption by inducing ROS produc-
tion.21,48,59 IL-33 plays a critical role in ozone-induced neutrophilic
rapid lung inflammation and bronchial epithelial barrier injury.
Microplastics and nanoplastics
The internalization of microplastics and nanoplastics into human lung
epithelial cells has been recently demonstrated.60 Microplastics can
cause cytotoxic and inflammatory responses by suppressing ZO-1
expression in HBECs through ROS.49
Detergents, surfactants, and enzymes
Surfactants, a main constituent in detergents, can significantly damage
the epithelial barrier because the detergent disrupts the lipid-lipid and
lipid-protein interactions of the membrane. Our group showed that
anionic surfactants can directly impair the TJ integrity of air-liquid
interface (ALI)–cultured normal human keratinocytes (NHEKs) and
HBECs.23,25 In addition, treatment with post-laundry detergent resi-
due was demonstrated to open the epithelial barrier in a dose-
dependent manner. RNA sequencing analysis indicates that exposure
to 50 000 times diluted detergents upregulated gene expression asso-
ciated with lipid metabolism, oxidative stress, and cell survival to com-
pensate the damage caused by the detergents to the cell membrane
lipids. Laundry detergents had no significant effect on chromatin
accessibility and DNA methylation in HBECs.23 Moreover, the marked
increase in Bacillus species–derived proteolytic enzymes in commer-
cial detergents was associated with the development of asthma and
rhinitis.61,62
Household cleaners, hand sanitizers, and disinfectants
Hand hygiene is one of the most important preventive measures for
contact transmission of severe acute respiratory syndrome coronavi-
rus 2 (SARS-CoV-2). The World Health Organization recommended
hand hygiene practices of using alcohol-based sanitizers and/or han-
dwashing with water and soap. An increased risk of hand eczema has
been reported in children and health care workers during the corona-
virus disease 2019 (COVID-19) pandemic.63,64
There is increasing evidence linking asthma to the use of respira-
tory irritant cleaning agents, mainly bleach, ammonia, and cleaning/
degreasing sprays. In addition, exposure to low molecular weight
agents/irritants in cleaning products and disinfectants is related to
adult-onset asthma.65,66
Emulsifiers in processed foods
Emulsifiers are frequently used as additives in the food industry.
There is evidence indicating that emulsifiers increase intestinal
permeability, even at low concentrations.67,68 Some commonly used
emulsifiers, including polysorbate 80 and carboxymethyl cellulose, sig-
nificantly increased bacterial translocation in Caco-2 cells derived
from a human colon carcinoma.27
High glucose-induced barrier defects
Thaiss et al showed that elevated glucose concentrations lead to
intestinal barrier dysfunction and enhanced dissemination of enteric
infection in a mouse model of type I diabetes mellitus induced by
administering streptozotocin.69 Similarly, Yu et al reported that high
glucose levels disrupted the TJs by downregulation of connexin
43, which plays a critical role in maintaining the function of the airway
epithelial barrier in the respiratory tract. 70
2 | ALLERGENS
The protease activity of allergens, such as house dust mites (HDMs),
Aspergillus fumigatus, and pollen, has been suggested to be involved in
the pathogenesis of allergic diseases by increasing the epithelial per-
meability and causing barrier dysfunction (previously reviewed).37,71
Proteolytically active allergens not only cleave the junction proteins
but also activate epithelial cells and adaptive immune responses
directly through protease-activated receptors (PARs).
HDM allergens increase the mucosal permeability of ALI-cultured
nasal epithelial cells (NECs) from HDM-induced AR patients.10 In addi-
tion, HDM perturb N-glycosylation of Toll-like receptor (TLR) 3 and
impair the interferon response, which may aggravate allergic lung
inflammation.72 Protease allergens, such as Dermatophagoides pte-
ronyssinus peptidase 1 (Der p 1) derived from HDM, induce type
2 inflammation, thereby promoting alarmins (IL-25, IL-33, TSLP) in
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epithelial cells.39,73 These cytokines activate ILC2 and promote type
2 helper cell differentiation.14,15 Hiraishi et al showed that fungal-
associated proteases induce ILC-mediated airway eosinophilia
through the expression of IL-25, IL-33, and TSLP.74 Unlike other pro-
tease allergens, Der f3 from Dermatophagoides farinae (Der f) induces
pro-inflammatory mediators (IL-6, IL-8, and granulocyte-macrophage
colony-stimulating factor), but not IL-25, IL-33, and TSLP, and causes
barrier dysfunction through PAR-1 and PAR-2.75 Allergen immuno-
therapy has been used for the treatment of allergic diseases.76-79
Yuan et al reported that allergen-specific immunotherapy restored
airway epithelial integrity, and attenuated IL-25–induced epithelial
endoplasmic reticulum stress and epithelial apoptosis in a Der f -induced
airway inflammation model.80
Pollen is also a well-known trigger of respiratory allergies and
asthma. Vinhas et al found that pollen proteases damage the epithelial
barrier via PARs.81 Consistently, Cleemput et al showed that pollen
proteases selectively and irreversibly damage the integrity and
anchorage of columnar respiratory epithelial cells. In addition, this
partial loss of barrier function facilitates the invasion of alpha-
herpesviruses.82
3 | MICROBIOTA CHANGES
The human body is colonized by a diverse microbial flora that plays an
essential role in human health and disease. As the outermost compo-
nent, the skin microbiota is the first line of defense against pathogenic
microorganisms. It is known that healthy skin microbiota limits patho-
gen colonization via competition for space and nutrients, altering skin
pH, and producing antimicrobial peptides (AMPs).83 Skin injury
induced by tape-stripping in mice disturbs the skin barrier and alters
the skin microbiota and host genes.84 It is well-known that poor
microbiome diversity is accompanied by an increase in Staphylococcus
aureus (S. aureus) abundance, which is positively correlated with AD
disease severity.85-87 Recently we also demonstrated that S. aureus is
significantly more abundant in lesional skin compared to nonlesional
and healthy skin.39 Moreover, when performing next-generation
sequencing on matched lesional and nonlesional skin tissue biopsy
specimens from patients with AD and healthy subjects, we identified
four TJs genes (CLDN4, CLDN5, TJP1, and TJP2) that are robustly cor-
related to microbiome dysbiosis in patients with AD.39,88 Consistent
with these results, Clausen et al reported that the microbiome alpha
diversity is lower in patients with AD compared with healthy controls
and is inversely correlated with disease severity, not only for lesional
skin but also nonlesional skin. Filaggrin gene mutations were associ-
ated with microbiome composition in the nonlesional skin of patients
with AD.89 Of interest, we found that S. aureus and Staphylococcus
epidermidis enhance the expression of TJs in healthy nasal tissue, but
not in nasal polyps.88,89 The microbiome may have a protective role as
observed in healthy epithelial cells. S. aureus–secreted proteins may
be contributing to the initiation and acute exacerbations of human
asthma and CRS with nasal polyps.90 Recent reports suggest that early
life bacterial supplementation may prevent the onset and progression
of allergic diseases.91 On the other hand, Roßberg et al reported that
applying bacterial lysates of heat-killed gram-negative Escherichia coli
and gram-positive Enterococcus faecalis in early infancy does not influ-
ence the development of AD, AR, asthma, and sensitization at school
age.92
It is widely accepted that the epithelial barrier is armed with
its own protective mechanisms. Epithelial cells sense pathogen-
associated molecular patterns by expressing pattern-recognition
receptors, including TLR and PAR. It is known that TLR2 is essential
for maintaining epithelial barrier function.93,94 In line with these stud-
ies, Ruffner et al found that TLR2 stimulation induces claudin-1 and
ZO-1 production in esophageal epithelial cells and increases histone
4 acetylation in claudin-1 gene enhancer and promoter.95 Decreased
expression of TLR2 on Langerhans cells in AD skin impairs S. aureus–
derived signals and contributes to the immune deviation from S. aureus
clearance.96 Microbial DNA sequences containing unmethylated CpG
dinucleotides activate TLR9, restoring epithelial barrier integrity by
modulating TJ expression.97 Furthermore, probiotic bacteria, mostly
lactobacilli, interact with the epithelial barrier and immune cells through
pattern recognition receptors and promote the expression of TJs and
AJs, restoring the epithelial barrier integrity.98
S. aureus induces proinflammatory cytokines, such as tumor
necrosis factor α (TNF-α) in keratinocytes. We showed that TNF-α
and TNF-like weak inducer of apoptosis (TWEAK) cooperate in the
induction of apoptosis in primary keratinocytes and that a high
TWEAK expression is observed in lesional AD skin.99
3.1 | Mechanism of barrier dysfunction
3.1.1 | Cytokines and hormonal factors
It is well-established that signature type 2 cytokines, such as IL-4 and
IL-13, impair the epithelial barrier function, reducing the expression of
TJs proteins and filaggrin.7,38 100 For example, IL-4 and IL-13 down-
regulate claudin-4, ZO-1, and occludin in HBECs, which results in
increased paracellular leakiness and respiratory hyper-responsive-
ness.101 On the other hand, Sweerus et al reported that IL-13 down-
regulates the expression of claudin-18 but not of claudin-1, -4, and
-7.102 A recent systematic review showed that anti–IL-4 and IL-13
receptor monoclonal antibodies (dupilumab), anti–IL-5 monoclonal
antibodies (mepolizumab and reslizumab), and anti–IL-5 receptor
alpha monoclonal antibodies (benralizumab) are effective treatments
for severe asthma and AD.103-109 Type 2 cytokines can cause barrier
dysfunction by downregulating filaggrin gene expression. Mitamura
et al reported that IL-24, a member of the IL-20 family, mediates the
IL-13–induced downregulation of filaggrin gene expression.110 Single-
cell analysis of biopsy samples and blisters showed that the frequen-
cies of type 2 (IL13+)/type 22(IL22+) T cells are higher than those of
type 1 (IFN-γ+) in lesional AD, whereas this ratio is slightly reduced in
nonlesional AD.111-113
Epithelium-derived alarmins, IL-25, IL-33, and TSLP, lead to sys-
temic inflammation characterized by activation of ILC2, exacerbated
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eosinophilia and IgE/IgG1 production and induce an immune response
toward inhaled noxious agents and allergens.114,115 Xiong et al found
that leukotriene B4 induces IL-33 expression and ILC2 activation in the
lungs via engagement of its receptor 1 (BLT1) in a papain-induced lung
inflammation mouse model.116 ILC2s also play an essential role in dis-
rupting the epithelial barrier. We demonstrated that IL-13 produced by
ILC2s induces keratinocyte and bronchial epithelial barrier disruption
via downregulation of the expression of TJ components.8,117
The common inflammatory cascade in allergic diseases is initiated
by an IgE-dependent mast cell degranulation with the release of hista-
mine, among other mediators, and is further orchestrated by type
2 cytokines.118,119 Gschwandtner et al first demonstrated that hista-
mine aggravates the severity of AD and that anti-histamines may have
potential therapeutic value to restore skin barrier function in these
patients.119 Of interest, histamine directly inhibits the expression of
filaggrin, loricrin, claudin-1, claudin-4, and occludin in keratinocytes.119
Histamine and Th2 cells are critical factors in initiating and maintaining
a leaky barrier in patients via histamine receptor 1 with an early phase
allergic airway response.120 Leukotriene E4, an arachidonic acid–
derived bioactive molecule, mediates eosinophilic airway inflammation
by decreasing the level of surfactant protein D.121 On the other hand,
prostaglandin D2, which is also a potent pro-inflammatory lipid media-
tor, has been reported to have protective effects in acute lung injury122
and later phase skin and airway inflammation.123 Chymases are a family
of serine proteases found primarily in mast cells. Zhou et al reported
that chymase suppresses the expressions of occludin, claudin-4, ZO-1,
E-cadherin, focal adhesion kinase, and cytokeratin, resulting in dysfunc-
tion of the airway wall in the pathogenesis of asthma.124 Moreover, an
impaired epithelial barrier facilitates allergen passage and mast cell
degranulation even in the absence of allergic inflammation.125
4 | GENETICS AND EPIGENETICS OF
EPITHELIAL BARRIER LEAKINESS
Recent studies have shown that epigenetic mechanisms mediate the
effect of environmental and inflammatory triggers associated with
allergic diseases.126,127 Histone acetylation induced by histone
acetyltransferases is associated with gene transcription. On the other
hand, histone deacetylases (HDACs) suppress gene transcription. Of
interest, Nicodemus-Johnson et al showed that exposure of HBEC to
IL-13 changes global DNA methylation patterns and results in long-
lasting epigenetic changes near asthma-associated genes.128 More-
over, we found that IL-4 and IL-13 increase HDAC activity, inducing
barrier leakiness in HBECs from patients with allergic asthma.100
Kaneko et al reported that HDAC inhibitors induce the expression of
claudin-1 and -4 and ciliogenesis via p63 in normal and diseased nasal
epithelium tissues.129 The role of HDAC in barrier dysfunction and
potential treatments using HDAC inhibitors are yet to be elucidated.
CpG sites are regions of DNA consisting of guanine and cytosine.
The methylation of CpG sites plays an important role in the regulation
of gene expression. We recently reported that an increased global
methylation level in HBEC from asthmatic individuals. Interestingly,
the inhibition of CpG methylation restores leakiness that was shown
in the asthmatic epithelium.130
Filaggrin loss-of-function mutations are associated with higher
total IgE levels, more sensitizations, and a more severe course of
AD.131,132 In humans, individuals with reduced filaggrin gene expres-
sion levels exhibit early onset AD that is closely associated with
asthma and food allergy, compared to subjects with normal filaggrin
gene expression levels.133,134 Renert-Yuval et al showed comparative
skin biopsy profiles of AD across different age groups and found that
only adults had a significant reduction in filaggrin expression.135 The
human filaggrin gene (FLG) is polymorphic with an intragenic copy
number variation. Specifically, 10, 11, or 12 nearly identical tandem
repeats can be present in exon 3. Not only loss-of-function mutation,
but also low copy numbers of filaggrin affect AD risk.136
4.1 | Detection of skin barrier dysfunction
Quantitative skin barrier assessment in vivo has potential value in many
clinical applications, including diagnosis, follow-up, prevention, and
therapy evaluation. Several invasive and non-invasive methods have
been developed to study the barrier function. The measurement of skin
hydration, colorimetry, skin surface pH, and sebometry are all examples
of non-invasive methods. However, these methods provide only limited
information on different skin characteristics and conditions and do not
directly measure the skin barrier function.137 TEWL is the amount of
water that evaporates passively from the surface of the skin and its
measurement allows for quantification of skin barrier dysfunction.138
However, TEWL can be affected by several environmental factors.
Indeed, its accuracy is dependent on humidity, temperature, and skin
hydration level. In diseased skin, TEWL is higher due to damage in the
skin barrier and/or alterations in keratinization.138,139
Confocal Raman spectroscopy is another non-invasive method to
characterize the molecular composition of the skin in vivo by irradiat-
ing the sample with low-power monochromatic laser light. After the
incident light excites the molecules within the tissue, the light is
reflected in a wavelength characteristic of each skin component.
The scattered light is then captured and analyzed, thus allowing
non-invasive in vivo measurements at different depths within the
tissue.140 Several studies have suggested that the confocal Raman
spectroscopy is useful for the detection of FLG-related AD skin
barrier by assessing the reduction of natural moisturizing factors,
which are driven from the breakdown of FLGs.141-143 A recent study
used confocal Raman spectroscopy to quantify the amount of water,
ceramide, and urocanic acid in the skin, and found reduced levels of
these components in atopic skin and a decreased lipid-to-protein
ratio, suggesting the potential use of this technique for the stratifica-
tion of AD patients.144
A promising non-invasive tool for detecting skin barrier function
in vivo is represented by electrical impedance spectroscopy (EIS).
The electrical impedance of a tissue measured at various frequencies
provides information about its structure and integrity, reflecting its
pathophysiological status because normal and pathologic tissues differ
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in cell size, shape, orientation, compactness, and membrane struc-
tures.145-147 Current EIS applications include the diagnosis of malig-
nant tissues in melanoma, breast tissue, prostate, and skin, and the
characterization of tissue changes after ischemia.147-150 Recently,
Rinaldi et al demonstrated EIS as a tool for the characterization of the
epithelial barrier function in vivo.151,152 In the first group of studies in
mice, EIS appeared to be a useful and reliable tool for detecting skin
barrier defects. After experimentally damaging the skin barrier by tape
stripping and epicutaneous application of proteases, such as papain,
trypsin, and cholera toxin, a significant reduction in skin electrical
impedance was observed. The findings were inversely correlated with
TEWL.151 In a clinical study of AD patients, EIS was used to measure
the skin barrier status with good specificity and sensitivity between
controls, non-lesional skin of AD, and lesional skin of AD patients.152
EIS was also useful in assessing skin lesion healing in response to
treatment, correlating with the disease score SCORAD and pruritus
score, confirming that EIS has clinical potential for objective disease
assessment and lesion follow-up in AD.152 Furthermore, EIS measure-
ments on the non-lesional skin of AD patients correlated with the
number of tandem repeats in the FLG gene. EIS has many potential
clinical applications (Figure 3). We consider that it may be useful for
identifying infants with a high risk of developing AD in a simple, fast
and non-invasive manner. Preventive therapies can be recommended
to strengthen the skin barrier function and simultaneously avoiding
exposure to environmental factors. There is a current need to develop
novel tools for monitoring skin in AD patients to predict exacerbations
and lesion follow-up in response to therapy.
5 | CONCLUSION
A dysfunctional epithelial barrier might facilitate the uptake of aller-
gens and exogenous particles, leading to lesional inflammation. Aller-
gen entry through a leaky epithelial barrier may cause systemic atopic
responses that contribute to the atopic march. Understanding the
underlying mechanisms involved in epithelial dysfunction is essential
for developing novel strategies for the prevention and treatment of
allergic diseases.
There is a pressing need to improve our understanding of the
factors and molecular mechanisms associated with “leaky epithelial
barriers.” Experimental models and skin organoids should be devel-
oped to study the passage of allergens across a leaky epithelial bar-
rier. There is strong evidence linking barrier leakiness and
inflammatory skin diseases, which needs to be considered when
developing novel strategies for its prevention, early intervention,
and diagnosis. Numerous strategies target the epithelial barrier
including avoidance and dose control of hazardous products
together with the development of safer alternatives, clinical appli-
cation of EIS for the identification of individuals with a leaky bar-
rier, development of therapeutic approaches for restoring the
F IGURE 3 Detection of epithelial
barrier function by electric impedance
spectroscopy. Quantitative skin barrier
assessment in vivo can provide valuable
information for the prevention, diagnosis,
and monitoring treatment response of AD
patients. Electrical impedance spectroscopy
(EIS) can be useful for identifying infants
with a high risk of developing AD by
measuring the integrity of the epithelial
barrier. EIS can be a valuable tool for
precision medicine to prevent the atopic
march, exacerbation, and relapse of AD
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epithelial barrier integrity, and interventions through diet and
microbiome.
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